FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981522045> ?p ?o ?g. }

• W1981522045 endingPage "S264" @default.
• W1981522045 startingPage "S264" @default.
• W1981522045 abstract "ObjectiveThe purpose of this study was to compare the use of single dose gonadotropin releasing hormone (GnRH) antagonist (0.25 mg) versus coasting for the prevention of severe ovarian hyperstimulation syndrome (OHSS) in patients with high risk undergoing invitro fertilization/intracytoplasmic sperm injection (IVF/ICSI).DesignRetrospective study.Materials and MethodsPatients undergoing IVF/ICSI with the long GnRH agonist protocol were identified as high responders based on the serum E2 level >3000 pg/ml and the multiple follicular development on the day of human chorionic gonadotropin (hCG) administration. Eighty six severely overstimulated IVF/ICSI patients with the long GnRH agonist protocol were enrolled the study and were consecutively assigned to either coasting group (Group A, n=42) and single dose GnRH antagonist (0.25 mg) treatment group (Group B, n=44). Patients treated with a single dose GnRH antagonist 0.25 mg on the day before hCG administration in group B. In group A, the duration of coasting prior to hCG administration was 2 days. Recombinant hCG 250 mcg was given to all patients when following a drop in serum E2 levels. Outcome measures included OHSS incidence rates and pregnancy rates in the two trial groups.ResultsEstradiol levels were decreased significantly both of the groups. There was no difference in the incidence of moderate and severe OHSS between the groups. One of the 42 patients in the coasted group developed severe OHSS and three developed moderate OHSS. In the single dose GnRH antagonist group, one of the 44 developed severe OHSS and four developed moderate OHSS.There were no significant differences between the two groups comparing serum E2 levels on the day of hCG administration, the number of oocytes retrieved, fertilization and pregnancy rates.ConclusionThe administration of single dose 0.25 mg GnRH antagonist appears to be an effective alternative to coasting for the prevention of OHSS in IVF patients who are at risk with high E2 levels in a GnRH long agonist protocol. ObjectiveThe purpose of this study was to compare the use of single dose gonadotropin releasing hormone (GnRH) antagonist (0.25 mg) versus coasting for the prevention of severe ovarian hyperstimulation syndrome (OHSS) in patients with high risk undergoing invitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). The purpose of this study was to compare the use of single dose gonadotropin releasing hormone (GnRH) antagonist (0.25 mg) versus coasting for the prevention of severe ovarian hyperstimulation syndrome (OHSS) in patients with high risk undergoing invitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). DesignRetrospective study. Retrospective study. Materials and MethodsPatients undergoing IVF/ICSI with the long GnRH agonist protocol were identified as high responders based on the serum E2 level >3000 pg/ml and the multiple follicular development on the day of human chorionic gonadotropin (hCG) administration. Eighty six severely overstimulated IVF/ICSI patients with the long GnRH agonist protocol were enrolled the study and were consecutively assigned to either coasting group (Group A, n=42) and single dose GnRH antagonist (0.25 mg) treatment group (Group B, n=44). Patients treated with a single dose GnRH antagonist 0.25 mg on the day before hCG administration in group B. In group A, the duration of coasting prior to hCG administration was 2 days. Recombinant hCG 250 mcg was given to all patients when following a drop in serum E2 levels. Outcome measures included OHSS incidence rates and pregnancy rates in the two trial groups. Patients undergoing IVF/ICSI with the long GnRH agonist protocol were identified as high responders based on the serum E2 level >3000 pg/ml and the multiple follicular development on the day of human chorionic gonadotropin (hCG) administration. Eighty six severely overstimulated IVF/ICSI patients with the long GnRH agonist protocol were enrolled the study and were consecutively assigned to either coasting group (Group A, n=42) and single dose GnRH antagonist (0.25 mg) treatment group (Group B, n=44). Patients treated with a single dose GnRH antagonist 0.25 mg on the day before hCG administration in group B. In group A, the duration of coasting prior to hCG administration was 2 days. Recombinant hCG 250 mcg was given to all patients when following a drop in serum E2 levels. Outcome measures included OHSS incidence rates and pregnancy rates in the two trial groups. ResultsEstradiol levels were decreased significantly both of the groups. There was no difference in the incidence of moderate and severe OHSS between the groups. One of the 42 patients in the coasted group developed severe OHSS and three developed moderate OHSS. In the single dose GnRH antagonist group, one of the 44 developed severe OHSS and four developed moderate OHSS.There were no significant differences between the two groups comparing serum E2 levels on the day of hCG administration, the number of oocytes retrieved, fertilization and pregnancy rates. Estradiol levels were decreased significantly both of the groups. There was no difference in the incidence of moderate and severe OHSS between the groups. One of the 42 patients in the coasted group developed severe OHSS and three developed moderate OHSS. In the single dose GnRH antagonist group, one of the 44 developed severe OHSS and four developed moderate OHSS.There were no significant differences between the two groups comparing serum E2 levels on the day of hCG administration, the number of oocytes retrieved, fertilization and pregnancy rates. ConclusionThe administration of single dose 0.25 mg GnRH antagonist appears to be an effective alternative to coasting for the prevention of OHSS in IVF patients who are at risk with high E2 levels in a GnRH long agonist protocol. The administration of single dose 0.25 mg GnRH antagonist appears to be an effective alternative to coasting for the prevention of OHSS in IVF patients who are at risk with high E2 levels in a GnRH long agonist protocol." @default.
• W1981522045 created "2016-06-24" @default.
• W1981522045 creator A5013266261 @default.
• W1981522045 creator A5014392233 @default.
• W1981522045 creator A5015187420 @default.
• W1981522045 creator A5028636449 @default.
• W1981522045 creator A5081655366 @default.
• W1981522045 creator A5087052598 @default.
• W1981522045 date "2012-09-01" @default.
• W1981522045 modified "2023-09-30" @default.
• W1981522045 title "Coasting versus single dose GNnRH antagonist for the prevention of ovarian hyperstimulation syndrome" @default.
• W1981522045 doi "https://doi.org/10.1016/j.fertnstert.2012.07.963" @default.
• W1981522045 hasPublicationYear "2012" @default.
• W1981522045 type Work @default.
• W1981522045 sameAs 1981522045 @default.
• W1981522045 citedByCount "0" @default.
• W1981522045 crossrefType "journal-article" @default.
• W1981522045 hasAuthorship W1981522045A5013266261 @default.
• W1981522045 hasAuthorship W1981522045A5014392233 @default.
• W1981522045 hasAuthorship W1981522045A5015187420 @default.
• W1981522045 hasAuthorship W1981522045A5028636449 @default.
• W1981522045 hasAuthorship W1981522045A5081655366 @default.
• W1981522045 hasAuthorship W1981522045A5087052598 @default.
• W1981522045 hasBestOaLocation W19815220451 @default.
• W1981522045 hasConcept C126322002 @default.
• W1981522045 hasConcept C170493617 @default.
• W1981522045 hasConcept C2775948956 @default.
• W1981522045 hasConcept C2776537878 @default.
• W1981522045 hasConcept C2776885963 @default.
• W1981522045 hasConcept C2777886879 @default.
• W1981522045 hasConcept C2778278907 @default.
• W1981522045 hasConcept C2778478619 @default.
• W1981522045 hasConcept C2778575703 @default.
• W1981522045 hasConcept C2778894405 @default.
• W1981522045 hasConcept C2778938600 @default.
• W1981522045 hasConcept C2779192864 @default.
• W1981522045 hasConcept C2779234561 @default.
• W1981522045 hasConcept C2781065240 @default.
• W1981522045 hasConcept C29456083 @default.
• W1981522045 hasConcept C512716672 @default.
• W1981522045 hasConcept C54355233 @default.
• W1981522045 hasConcept C71315377 @default.
• W1981522045 hasConcept C71924100 @default.
• W1981522045 hasConcept C86803240 @default.
• W1981522045 hasConceptScore W1981522045C126322002 @default.
• W1981522045 hasConceptScore W1981522045C170493617 @default.
• W1981522045 hasConceptScore W1981522045C2775948956 @default.
• W1981522045 hasConceptScore W1981522045C2776537878 @default.
• W1981522045 hasConceptScore W1981522045C2776885963 @default.
• W1981522045 hasConceptScore W1981522045C2777886879 @default.
• W1981522045 hasConceptScore W1981522045C2778278907 @default.
• W1981522045 hasConceptScore W1981522045C2778478619 @default.
• W1981522045 hasConceptScore W1981522045C2778575703 @default.
• W1981522045 hasConceptScore W1981522045C2778894405 @default.
• W1981522045 hasConceptScore W1981522045C2778938600 @default.
• W1981522045 hasConceptScore W1981522045C2779192864 @default.
• W1981522045 hasConceptScore W1981522045C2779234561 @default.
• W1981522045 hasConceptScore W1981522045C2781065240 @default.
• W1981522045 hasConceptScore W1981522045C29456083 @default.
• W1981522045 hasConceptScore W1981522045C512716672 @default.
• W1981522045 hasConceptScore W1981522045C54355233 @default.
• W1981522045 hasConceptScore W1981522045C71315377 @default.
• W1981522045 hasConceptScore W1981522045C71924100 @default.
• W1981522045 hasConceptScore W1981522045C86803240 @default.
• W1981522045 hasIssue "3" @default.
• W1981522045 hasLocation W19815220451 @default.
• W1981522045 hasOpenAccess W1981522045 @default.
• W1981522045 hasPrimaryLocation W19815220451 @default.
• W1981522045 hasRelatedWork W2074723770 @default.
• W1981522045 hasRelatedWork W2117814169 @default.
• W1981522045 hasRelatedWork W2161415649 @default.
• W1981522045 hasRelatedWork W2371818489 @default.
• W1981522045 hasRelatedWork W2402097566 @default.
• W1981522045 hasRelatedWork W2782033710 @default.
• W1981522045 hasRelatedWork W3029392031 @default.
• W1981522045 hasRelatedWork W3032859893 @default.
• W1981522045 hasRelatedWork W4231694619 @default.
• W1981522045 hasRelatedWork W4239754205 @default.
• W1981522045 hasVolume "98" @default.
• W1981522045 isParatext "false" @default.
• W1981522045 isRetracted "false" @default.
• W1981522045 magId "1981522045" @default.
• W1981522045 workType "article" @default.